Elo Mutual Pension Insurance Co purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,860 shares of the company's stock, valued at approximately $326,000.
Several other institutional investors also recently modified their holdings of OGN. Horizon Bancorp Inc. IN raised its holdings in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares during the last quarter. Millstone Evans Group LLC bought a new stake in Organon & Co. during the fourth quarter valued at $29,000. Larson Financial Group LLC grew its holdings in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after acquiring an additional 1,734 shares during the period. Riverview Trust Co raised its position in shares of Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc lifted its stake in shares of Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after purchasing an additional 1,324 shares during the period. Institutional investors own 77.43% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a report on Friday, February 14th. Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.80.
Read Our Latest Research Report on Organon & Co.
Organon & Co. Stock Down 1.8 %
OGN stock traded down $0.27 during midday trading on Thursday, reaching $14.45. 1,579,815 shares of the company's stock traded hands, compared to its average volume of 2,552,433. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm's fifty day moving average price is $15.26 and its 200-day moving average price is $16.12. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 4.34, a P/E/G ratio of 0.90 and a beta of 0.76.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. As a group, sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.75%. Organon & Co.'s dividend payout ratio is presently 33.63%.
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
